June 28 Quick Takes: Roivant, Pfizer create start-up to house TYK2/JAK1 program
Plus Jazz’s Sativex misses and updates from Sanofi, Spero, SonALAsense and more
Roivant Sciences Ltd. and Pfizer Inc. (NYSE:PFE) said start-up Priovant Therapeutics is advancing dual TYK2 and JAK1 inhibitor brepocitinib (PF-06700841) in a Phase III trial to treat dermatomyositis and a Phase IIb trial to treat systemic lupus erythematosus. Pfizer owns 25% of the newco, which obtained a license to the therapy from the pharma in September 2021. The partners said Pfizer has tested the potential first-in-class therapy in more than 1,000 patients across multiple autoimmune indications.
In its earnings report for the fiscal year ended March 31, Roivant said it has discontinued a handful of programs from several of its affiliates. The group includes lentiviral therapy ARU-1801 from Aruvant Sciences Inc. to treat sickle cell disease; anti-infective LSVT-1701 from Lysovant Sciences Ltd.; dermatological treatments cerdulatinib, DMVT-504 and DMVT-503 from Dermavant Sciences Ltd.; and oncology therapy CVT-TCR-01 from Cytokine Sciences Ltd...